Clinical characteristics of patients undergoing surgical ventricular reconstruction by choice and by randomization

Marian Zembala, Robert E. Michler, Andrzej Rynkiewicz, Thao Huynh, Lilin She, Barbara Lubiszewska, James A. Hill, Ruzena Jandova, Francois Dagenais, Eric D. Peterson, Robert H. Jones

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objectives: The aim of this study was to confirm the generalizability of the conclusions of the STICH (Surgical Treatment for Ischemic Heart Failure) trial. Background: Surgical ventricular reconstruction (SVR) added to coronary artery bypass grafting (CABG) did not decrease death or cardiac hospitalization in STICH patients randomized to CABG with (n = 501) or without (n = 499) SVR. Methods: Baseline clinical characteristics of 1,000 STICH SVR hypothesis patients and 1,036 STICH-eligible Society of Thoracic Surgeons (STS) National Cardiac Database patients undergoing CABG plus SVR were entered into a multivariate model equation to predict a mortality that placed these 2,036 patients in 1 of 32 risk at randomization (RAR) groups. The number of patients in each RAR group profiled the risk of STICH treatment arms and of STICH and STS STICH-eligible patients. Results: That 85% of the 1,000 STICH patients known to have no significant differences in baseline characteristics between the 2 treatment arms shared the same RAR group suggests that the RAR methodology has sufficient accuracy to compare RAR profiles of STICH and STS patients. RAR group was shared by 1,522 of 2,036 STICH and STS STICH-eligible patients (75%) who underwent CABG plus SVR. Differences in baseline characteristics responsible for more low-risk STICH patients and more high-risk STS patients were modest. Cox proportional hazard ratios of 1,000 STICH patients in 3 RAR groups suggested by STICH and STS RAR differences showed no differential treatment effect on survival across the low-, intermediate-, and high-risk groups. Conclusions: The STICH conclusion of no benefit from adding SVR to CABG applies to a broad spectrum of CABG-eligible patients with ischemic cardiomyopathy. (Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease; NCT00023595)

Original languageEnglish (US)
Pages (from-to)499-507
Number of pages9
JournalJournal of the American College of Cardiology
Volume56
Issue number6
DOIs
StatePublished - Aug 3 2010

Fingerprint

Random Allocation
Heart Failure
Coronary Artery Bypass
Therapeutics
Thorax
Cardiomyopathies

Keywords

  • ortality prediction
  • randomized clinical trial
  • schemic cardiomyopathy
  • surgical ventricular reconstruction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Clinical characteristics of patients undergoing surgical ventricular reconstruction by choice and by randomization. / Zembala, Marian; Michler, Robert E.; Rynkiewicz, Andrzej; Huynh, Thao; She, Lilin; Lubiszewska, Barbara; Hill, James A.; Jandova, Ruzena; Dagenais, Francois; Peterson, Eric D.; Jones, Robert H.

In: Journal of the American College of Cardiology, Vol. 56, No. 6, 03.08.2010, p. 499-507.

Research output: Contribution to journalArticle

Zembala, M, Michler, RE, Rynkiewicz, A, Huynh, T, She, L, Lubiszewska, B, Hill, JA, Jandova, R, Dagenais, F, Peterson, ED & Jones, RH 2010, 'Clinical characteristics of patients undergoing surgical ventricular reconstruction by choice and by randomization', Journal of the American College of Cardiology, vol. 56, no. 6, pp. 499-507. https://doi.org/10.1016/j.jacc.2010.03.054
Zembala, Marian ; Michler, Robert E. ; Rynkiewicz, Andrzej ; Huynh, Thao ; She, Lilin ; Lubiszewska, Barbara ; Hill, James A. ; Jandova, Ruzena ; Dagenais, Francois ; Peterson, Eric D. ; Jones, Robert H. / Clinical characteristics of patients undergoing surgical ventricular reconstruction by choice and by randomization. In: Journal of the American College of Cardiology. 2010 ; Vol. 56, No. 6. pp. 499-507.
@article{1303e815e33a4476b44ad55a0f6f01c0,
title = "Clinical characteristics of patients undergoing surgical ventricular reconstruction by choice and by randomization",
abstract = "Objectives: The aim of this study was to confirm the generalizability of the conclusions of the STICH (Surgical Treatment for Ischemic Heart Failure) trial. Background: Surgical ventricular reconstruction (SVR) added to coronary artery bypass grafting (CABG) did not decrease death or cardiac hospitalization in STICH patients randomized to CABG with (n = 501) or without (n = 499) SVR. Methods: Baseline clinical characteristics of 1,000 STICH SVR hypothesis patients and 1,036 STICH-eligible Society of Thoracic Surgeons (STS) National Cardiac Database patients undergoing CABG plus SVR were entered into a multivariate model equation to predict a mortality that placed these 2,036 patients in 1 of 32 risk at randomization (RAR) groups. The number of patients in each RAR group profiled the risk of STICH treatment arms and of STICH and STS STICH-eligible patients. Results: That 85{\%} of the 1,000 STICH patients known to have no significant differences in baseline characteristics between the 2 treatment arms shared the same RAR group suggests that the RAR methodology has sufficient accuracy to compare RAR profiles of STICH and STS patients. RAR group was shared by 1,522 of 2,036 STICH and STS STICH-eligible patients (75{\%}) who underwent CABG plus SVR. Differences in baseline characteristics responsible for more low-risk STICH patients and more high-risk STS patients were modest. Cox proportional hazard ratios of 1,000 STICH patients in 3 RAR groups suggested by STICH and STS RAR differences showed no differential treatment effect on survival across the low-, intermediate-, and high-risk groups. Conclusions: The STICH conclusion of no benefit from adding SVR to CABG applies to a broad spectrum of CABG-eligible patients with ischemic cardiomyopathy. (Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease; NCT00023595)",
keywords = "ortality prediction, randomized clinical trial, schemic cardiomyopathy, surgical ventricular reconstruction",
author = "Marian Zembala and Michler, {Robert E.} and Andrzej Rynkiewicz and Thao Huynh and Lilin She and Barbara Lubiszewska and Hill, {James A.} and Ruzena Jandova and Francois Dagenais and Peterson, {Eric D.} and Jones, {Robert H.}",
year = "2010",
month = "8",
day = "3",
doi = "10.1016/j.jacc.2010.03.054",
language = "English (US)",
volume = "56",
pages = "499--507",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Clinical characteristics of patients undergoing surgical ventricular reconstruction by choice and by randomization

AU - Zembala, Marian

AU - Michler, Robert E.

AU - Rynkiewicz, Andrzej

AU - Huynh, Thao

AU - She, Lilin

AU - Lubiszewska, Barbara

AU - Hill, James A.

AU - Jandova, Ruzena

AU - Dagenais, Francois

AU - Peterson, Eric D.

AU - Jones, Robert H.

PY - 2010/8/3

Y1 - 2010/8/3

N2 - Objectives: The aim of this study was to confirm the generalizability of the conclusions of the STICH (Surgical Treatment for Ischemic Heart Failure) trial. Background: Surgical ventricular reconstruction (SVR) added to coronary artery bypass grafting (CABG) did not decrease death or cardiac hospitalization in STICH patients randomized to CABG with (n = 501) or without (n = 499) SVR. Methods: Baseline clinical characteristics of 1,000 STICH SVR hypothesis patients and 1,036 STICH-eligible Society of Thoracic Surgeons (STS) National Cardiac Database patients undergoing CABG plus SVR were entered into a multivariate model equation to predict a mortality that placed these 2,036 patients in 1 of 32 risk at randomization (RAR) groups. The number of patients in each RAR group profiled the risk of STICH treatment arms and of STICH and STS STICH-eligible patients. Results: That 85% of the 1,000 STICH patients known to have no significant differences in baseline characteristics between the 2 treatment arms shared the same RAR group suggests that the RAR methodology has sufficient accuracy to compare RAR profiles of STICH and STS patients. RAR group was shared by 1,522 of 2,036 STICH and STS STICH-eligible patients (75%) who underwent CABG plus SVR. Differences in baseline characteristics responsible for more low-risk STICH patients and more high-risk STS patients were modest. Cox proportional hazard ratios of 1,000 STICH patients in 3 RAR groups suggested by STICH and STS RAR differences showed no differential treatment effect on survival across the low-, intermediate-, and high-risk groups. Conclusions: The STICH conclusion of no benefit from adding SVR to CABG applies to a broad spectrum of CABG-eligible patients with ischemic cardiomyopathy. (Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease; NCT00023595)

AB - Objectives: The aim of this study was to confirm the generalizability of the conclusions of the STICH (Surgical Treatment for Ischemic Heart Failure) trial. Background: Surgical ventricular reconstruction (SVR) added to coronary artery bypass grafting (CABG) did not decrease death or cardiac hospitalization in STICH patients randomized to CABG with (n = 501) or without (n = 499) SVR. Methods: Baseline clinical characteristics of 1,000 STICH SVR hypothesis patients and 1,036 STICH-eligible Society of Thoracic Surgeons (STS) National Cardiac Database patients undergoing CABG plus SVR were entered into a multivariate model equation to predict a mortality that placed these 2,036 patients in 1 of 32 risk at randomization (RAR) groups. The number of patients in each RAR group profiled the risk of STICH treatment arms and of STICH and STS STICH-eligible patients. Results: That 85% of the 1,000 STICH patients known to have no significant differences in baseline characteristics between the 2 treatment arms shared the same RAR group suggests that the RAR methodology has sufficient accuracy to compare RAR profiles of STICH and STS patients. RAR group was shared by 1,522 of 2,036 STICH and STS STICH-eligible patients (75%) who underwent CABG plus SVR. Differences in baseline characteristics responsible for more low-risk STICH patients and more high-risk STS patients were modest. Cox proportional hazard ratios of 1,000 STICH patients in 3 RAR groups suggested by STICH and STS RAR differences showed no differential treatment effect on survival across the low-, intermediate-, and high-risk groups. Conclusions: The STICH conclusion of no benefit from adding SVR to CABG applies to a broad spectrum of CABG-eligible patients with ischemic cardiomyopathy. (Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease; NCT00023595)

KW - ortality prediction

KW - randomized clinical trial

KW - schemic cardiomyopathy

KW - surgical ventricular reconstruction

UR - http://www.scopus.com/inward/record.url?scp=77955487135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955487135&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2010.03.054

DO - 10.1016/j.jacc.2010.03.054

M3 - Article

C2 - 20670761

AN - SCOPUS:77955487135

VL - 56

SP - 499

EP - 507

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 6

ER -